U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07774390) titled 'Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL' on July 31.
Brief Summary: This study is focused on tracking the long-term health of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) treated with a combination of two drugs, ibrutinib and venetoclax, as part of the original CAPTIVATE clinical trial.
Purpose and Goals While new treatments have significantly improved survival for patients with CLL, the disease remains incurable and often requires multiple rounds of treatment over a person's life. The primary goal of this study is to understand what happens to patients after they have completed t...